Oral iodinated activated charcoal improves lung function in patients with COPD

Area of Science:

• Pulmonary Medicine
• Pharmacology

Background:

• Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with limited treatment options.
• Current COPD therapies focus on bronchodilation and inflammation reduction, but lung function improvements are often modest.

Purpose of the Study:

• To evaluate the effect of oral iodinated activated charcoal (IAC) on lung function in patients with moderate COPD.
• To assess the safety and tolerability of IAC treatment in this patient population.

Main Methods:

• A double-blind, randomized, placebo-controlled, parallel-group study involving 40 patients with moderate COPD.
• Patients received either IAC or placebo for 8 weeks.
• Lung function was assessed by measuring FEV1 (Forced Expiratory Volume in 1 second) at baseline, post-bronchodilator, and post-exercise.

Main Results:

• Patients treated with IAC demonstrated a statistically significant improvement in baseline FEV1 by 130 ml (8.2%) compared to placebo (p = 0.031).
• Improved baseline FEV1 correlated with post-bronchodilator and post-exercise FEV1 values, indicating no ceiling effect on lung function improvement.
• Transient abnormal thyroid hormone levels were observed in 8 IAC patients, unrelated to lung function improvement; no serious adverse events were recorded.

Conclusions:

• Oral IAC administration significantly improved lung function in patients with moderate COPD.
• The mechanism of action for IAC's effect on COPD lung function is currently unknown and appears distinct from existing therapies.
• Further research is recommended to confirm clinical efficacy and elucidate the underlying mechanisms of IAC in COPD management.